Form 8-K · Current Report · Filed 2024-05-02
Moderna Reports Q1 2024 Financial Results and Business Updates
Moderna, Inc. reported its financial results for the first quarter of 2024, revealing total revenues of $167 million, a GAAP net loss of $1.2 billion, and GAAP diluted EPS of $(3.07). The company's revenue decline was primarily due to reduced sales of its COVID-19 vaccine. Moderna also announced the initiation of three new clinical studies for its individualized neoantigen therapy in combination with Merck's Keytruda for various cancers. Additionally, the company advanced three new vaccine programs towards Phase 3 clinical trials. Moderna reaffirmed its 2024 expected product sales of approximately $4 billion and anticipates numerous product milestones across its vaccines and therapeutics portfolio.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-24-000023
- CIK
- 0001682852
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$111.46
Next session
+12.1%
Since filing
-50.8%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Exhibits (1)
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.